Ph.D. Jonathan M. Rothberg - 22 May 2026 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: HYPR
Reported as of: 22 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:34:21 UTC
Prior SEC filing: 20 May 2026
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Anne Bruno, Attorney-in-Fact for Jonathan M. Rothberg, Ph.D.

Key filing fact

Ph.D. Jonathan M. Rothberg filed Form 4 for Hyperfine, Inc. (HYPR) on 22 May 2026.

Key facts

This page summarizes Ph.D. Jonathan M. Rothberg's Form 4 filing for Hyperfine, Inc. (HYPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 May 2026, 16:34.

Change

Previous filing in this sequence was filed on 20 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001076352 Primary reporting owner

ROTHBERG JONATHAN M

Relationship: Director, 10%+ Owner
Address: C/O HYPERFINE, INC., 351 NEW WHITFIELD STREET, GUILFORD
Signature: /s/ Anne Bruno, Attorney-in-Fact for Jonathan M. Rothberg, Ph.D.
Signature date: 22 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HYPR transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +157,700
Change %
Price: $0.000000^*
Shares after: 157,700
Date: 22 May 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 157,700
Exercise price: $1.49
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Rothberg's continued service through the applicable vesting date.